ResearcherUniversity of VeronaActive in the last 2 years
Vanja Vaccaro
Matched on OpenAlex author ID A5111493709. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 51
2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper
Papers 13
- Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
- The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
- Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Last author DOI 10.1016/j.esmoop.2022.100777↗
- Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗
- From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. Co-author DOI 10.3390/cells9020309↗
- Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. Co-author DOI 10.3390/ijms21228841↗
- Metastatic pancreatic cancer: Is there a light at the end of the tunnel? Co-author DOI 10.3748/wjg.v21.i16.4788↗
- A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Co-author DOI 10.2217/pgs.13.225↗
- Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Co-author DOI 10.1002/ijc.28078↗
- First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. Co-author DOI 10.3748/wjg.v19.i28.4511↗
- Molecular and genetic bases of pancreatic cancer. Co-author DOI 10.2174/138945012800564077↗
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmc1107627↗
- Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Co-author DOI 10.1517/14728222.2011.607438↗
Closest collaborators
The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michèle Milella · 9 shared papers, 2011–2024 · strength 0.65
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Paper The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic … DOI 10.1002/cam4.6111↗
- Paper Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precis… DOI 10.3390/ijms21228841↗
- Davide Melisi · 4 shared papers, 2011–2024 · strength 0.40
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Paper The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic … DOI 10.1002/cam4.6111↗
- Paper From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. DOI 10.3390/cells9020309↗
- Elisa Giommoni · 3 shared papers, 2021–2024 · strength 0.39
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Paper The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic … DOI 10.1002/cam4.6111↗
- Paper Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Stu… DOI 10.3390/curroncol28030164↗
- Guido Giordano · 3 shared papers, 2021–2024 · strength 0.39
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Paper The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic … DOI 10.1002/cam4.6111↗
- Paper Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Stu… DOI 10.3390/curroncol28030164↗
- Giampaolo Tortora · 3 shared papers, 2011–2024 · strength 0.29
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Paper Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Stu… DOI 10.3390/curroncol28030164↗
- Paper Emerging pathways and future targets for the molecular therapy of pancreatic cancer. DOI 10.1517/14728222.2011.607438↗
- Letizia Procaccio · 2 shared papers, 2023–2024 · strength 0.28
- Sara Lonardi · 2 shared papers, 2023–2024 · strength 0.28
- Ferdinando De Vita · 2 shared papers, 2023–2024 · strength 0.28
- Francesca Bergamo · 2 shared papers, 2023–2024 · strength 0.28
- Alberto Zaniboni · 2 shared papers, 2023–2024 · strength 0.28
- Lorenzo Antonuzzo · 2 shared papers, 2021–2023 · strength 0.25
- Paper The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic … DOI 10.1002/cam4.6111↗
- Paper Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Stu… DOI 10.3390/curroncol28030164↗
- Enrico Vasile · 3 shared papers, 2013–2024 · strength 0.22
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Paper A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer pa… DOI 10.2217/pgs.13.225↗
- Paper Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism … DOI 10.1002/ijc.28078↗
- Chiara Bazzichetto · 2 shared papers, 2020 · strength 0.20
- Claudio Luchini · 2 shared papers, 2020 · strength 0.20
- Aldo Scarpa · 2 shared papers, 2020 · strength 0.20
- Vincenzo Ricci · 1 shared paper, 2024 · strength 0.15
- Daniele Santini · 1 shared paper, 2024 · strength 0.15
- Matteo Landriscina · 1 shared paper, 2024 · strength 0.15
- Giovanni Lo Re · 1 shared paper, 2024 · strength 0.15
- Roberto Bianco · 1 shared paper, 2024 · strength 0.15
- Mario Scartozzi · 1 shared paper, 2023 · strength 0.13
- Andrea Pretta · 1 shared paper, 2023 · strength 0.13
- Simona Casalino · 1 shared paper, 2023 · strength 0.13
- Valeria Merz · 1 shared paper, 2023 · strength 0.13
- Morena Fasano · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.